September 30, 2021

GigaGen Licenses ProteoNic’s 2G UNic™ Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates

South San Francisco, Calif., September 30, 2021 (GLOBE NEWSWIRE) --  GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed a license agreement with Dutch biotech ProteoNic B.V. for the use of its premium 2G UnicTM technology platform to enable high-yield production of GigaGen’s mono- and polyclonal antibody drug candidates.

Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic’s technology platform for the development and manufacturing of GigaGen’s recombinant antibody drugs. Financial terms include upfront and maintenance payments, as well as milestone payments per product.

ProteoNic’s protein expression technology, 2G UNic improves recombinant protein production levels across a range of mammalian host cells, selection systems and protein targets. This is achieved via the combined effect of novel genetic elements, which together exert a positive effect on recombinant protein production levels. The technology increases production levels of complex proteins which are difficult to produce, including bi-specifics and fusion molecules and levels of products already in the multiple g/L range. Additionally, 2G UNic can be used to boost performance of other expression-enhancing technologies.